Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia

NeuroReport

Volumn 9, Issue 6, 1998, Pages 1191-1193

  Bond, Ann ^a   O'Neill, Michael J ^a   Hicks, Caroline A ^a   Monn, James A ^a   Lodge, David ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Global ischaemia; Metabotropic glutamate receptor; Neuroprotection

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; DIZOCILPINE; EGLUMETAD; GLUTAMATE RECEPTOR AGONIST; GYKI 53405; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TALAMPANEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; DRUG EFFICACY; GERBIL; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL;

EID: 0032550103     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199804200-00042     Document Type: Article

References (23)

1. Brierley TB. Cerebral hypoxia. In: Blackwood W and Corsellis A, eds. Greenfield's Neuropathology. London: Edward Arnold, 1976: 41-85.
2. Ito U, Spatz M, Walker T et al. Acts Neuropathol 32, 209-223 (1975).
3. Kirino T. Brain Res 239, 57-69 (1982).
4. Globus MY-T, Busto R, Dietrich WD et al. Neurosci Lett 91, 36-40 (1988).
5. Boast CA, Gerhardt SC, Pastor G et al. Brain Res 442, 345-348 (1988).
6. Gill R, Foster AC and Woodruff GN. Neuroscience 25, 847-855 (1988).
7. Sheardown MJ, Nielsen EO, Hansen AJ et al. Science 247, 571-574 (1990).
8. Lodge D, Bond A, O'Neill MJ et al. Neuropharmacology 12, 1681-1688 (1996).
9. Maginn M, Caldwell M, Kelly JP et al. Eur J Pharmacol 282, 259-262 (1995).
10. Opitz T, Richter P and Reymann KG. Neuropharmacology 5, 715-717 (1994).
11. Bond A, Monn JA and Lodge D. NeuroReport 8, 1463-1466 (1997).
12. Monn JA, Valli M, Massey SM et al. J Med Chem 40, 528-537 (1997).
13. Schoepp DD, Johnson BG, Wright RA et al. Neuropharmacology 1, 1-11 (1997).
14. Gill , Foster AC and Woodruff GN. J Neurosci 7, 3343-3349 (1987).
15. Bleakman D, Rusin KI, Chard PS et al. Mol Pharmacol 42, 192-196 (1992).
16. Bond A and Lodge D. Neuropharmacology 34, 1015-1023 (1995).
17. Schoepp DD and Conn PJ. Trends Pharmacol Sci 14, 13-20 (1993).
18. Battaglia G, Monn JA and Schospp DD. Neurosci Lett 229, 161-164 (1997).
19. Bruno V, Surenda FX, Storto M et al. J Neurosci 17, 1891-1897 (1997).
20. Bruno V, Copani A, Bonnano L et al. Eur J Pharmacol 310, 61-66 (1996).
21. Shinozaki H. Eur J Neurol 34 (Suppl.3), 2-9 (1994).
22. Chiamulera C, Albertini P, Valerio E et al. Eur J Pharmacol 216, 335-336 (1992).
23. Theriault E. US. Patent 5,607,973 (1997).